What Aravax does

Aravax is a clinical-stage biotechnology company founded in 2015 as a spinout from Alfred Health and Monash University in Melbourne, Australia, focused on developing next-generation peptide-based immunotherapies for food allergy. Its lead product candidate, PVX108, is composed of seven proprietary peptides representing immuno-dominant T-cell epitopes from major peanut allergens; the peptides are designed to retrain allergen-specific CD4+ T cells upstream of IgE-mediated processes without containing whole peanut proteins or triggering treatment-induced anaphylaxis. The candidate is administered as a monthly intradermal injection (0.1 mL) with no dose escalation required, differentiating from existing oral and epicutaneous approaches on safety, convenience, and disease-modifying mechanism. Phase 1 trials demonstrated a favorable safety profile even in patients with asthma and prior anaphylaxis, and a 95-patient Phase 2 study (AVX-201) is fully enrolled across 14 sites in the United States and Australia, with headline results expected in H1 2026.

The company is pre-revenue and funded primarily through venture capital, having closed a US$42.2M Series B in January 2024 led by Brandon Capital and Tenmile and joined by Novartis Venture Fund, Breakthrough Victoria, Uniseed, UniSuper, and Agati Capital. Its future revenue model contemplates one-time product licensing and pharmaceutical sales of PVX108 and pipeline food-allergy immunotherapies following regulatory approval, distributed eventually through allergists, immunologists, specialty pharmacies, and healthcare providers. Commercial readiness is being built through a UK subsidiary at the Oxford Science Park (established November 2024) for peptide manufacturing process development, alongside senior commercial, regulatory, and CMC hires. Aravax's go-to-market motion today centers on international clinical trial execution (Phase 2 under US IND and Australian regulatory frameworks), scientific engagement at conferences such as EAACI and AAAAI, and academic collaborations with Stanford, Benaroya Research Institute, and Murdoch Children's Research Institute.

Name

Aravax

Legal name

Aravax Pty Ltd

Website

https://aravax.com.au

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Aravax is a clinical-stage biotechnology company developing PVX108, a peptide-based immunotherapy designed to safely retrain the immune system to tolerate peanut allergens. The Melbourne-headquartered firm is running an international Phase 2 trial in children and adolescents ahead of a future commercial launch targeting allergists and food-allergy patients.

Ownership category

akta.pro rank

Product category

Allergy Immunotherapy Pharmaceuticals

akta.pro primary industry

Allergen Immunotherapy (SCIT/SLIT) Services (HLAKAAAF)

Keywords

• Peptide immunotherapy
• Peanut allergy treatment
• Biopharmaceutical research
• Food allergy therapies
• Clinical stage biotechnology

Headquarters

HQ city

Melbourne

HQ country

Australia

HQ region

Oceania

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

1. Pharmaceutical Product Revenue (Future): Pre-commercial biotech company. Future revenue expected from sale of PVX108 and pipeline immunotherapy products for food allergies upon regulatory approval. The company is preparing for Phase 3 trials and eventual market launch.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Aravax is a clinical-stage biotechnology company developing PVX108, a peptide-based immunotherapy composed of seven proprietary peptides targeting T cells for the treatment of peanut allergy. The therapy is delivered via monthly intradermal injection and is designed to retrain the immune system to tolerate peanut proteins without triggering treatment-induced acute allergic reactions. The company is currently running international Phase 2 clinical trials in the US and Australia and is preparing for Phase 3 development.

Product overview

Aravax is a clinical-stage biotechnology company developing next-generation, disease-modifying immunotherapies for food allergy. Its lead product candidate, PVX108, is a peptide-based immunotherapy in Phase 2 clinical trials for peanut allergy treatment. The company's proprietary platform uses engineered peptides to precisely target T cells and retrain the immune system to tolerate specific foods without triggering treatment-induced allergic reactions.

Differentiator

Problem solved

Functional benefit

Products and services

• PVX108 PVX108 is Aravax's lead peanut allergy immunotherapy candidate, composed of seven proprietary peptides representing immuno-dominant T cell epitopes from major peanut allergens. It is designed to retrain the immune system to tolerate peanut proteins by precisely targeting allergen-specific T cells, while avoiding the acute allergic reactions triggered by whole-allergen therapies. It is administered monthly via intradermal injection (0.1 mL) with no dose escalation required, and is being developed for children and adolescents (aged 4-17) with peanut allergy.

Quantifiable outcome

• Phase 1 trials demonstrated PVX108 was safe and well tolerated in participants with peanut allergy, including participants with asthma and prior anaphylaxis to peanut
• +2 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core and supporting.

• Benaroya Research InstitutecoreStrategic or Co-development PartnerResearch collaboration established January 2017. Erik Wambre's research group in Seattle collaborates on immunological response research. BRI received $5M NIH grant to support investigations into immune mechanisms of PVX108.
• Stanford UniversitycoreStrategic or Co-development PartnerResearch collaboration established November 2017 with Professor Kari Nadeau's group at Sean N. Parker Centre for Allergy and Asthma Research. Collaborates on exploring immunological responses to PVX108 using clinical samples from trials.
• Monash UniversitycoreTechnology or IntegrationTechnology and IP originated from Monash University and Alfred Health in 2015. Co-founder Sara Prickett held senior research posts here.
• Alfred HealthcoreTechnology or IntegrationTechnology and IP originated from Alfred Health and Monash University in 2015. Research led by Professor Robyn O'Hehir's team.
• Murdoch Children's Research InstitutesupportingStrategic or Co-development PartnerClinical trial site for Phase 2 (AVX-201) led by Associate Professor Kirsten Perrett. Also leads National Allergy Centre of Excellence.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Circassia Pharmaceuticals: Circassia is a UK-based allergy and respiratory specialty pharmaceutical company with a portfolio of allergy diagnostics and treatments. Several Aravax executives (Pascal Hickey, Paul Laidler, Adrian Parry, Louise Peacock) previously held senior roles at Circassia, indicating deep talent and strategic overlap in allergy therapeutics.
• Stallergenes Greer: Stallergenes Greer is a global leader in allergen immunotherapy, offering SCIT and SLIT products for respiratory and venom allergies. It is a broader incumbent in the allergy immunotherapy category relevant to Aravax's target market of allergists and represents the established commercial infrastructure Aravax will eventually need to compete with or partner through.
• ALK-Abello A/S: ALK-Abello is the dominant global player in allergy immunotherapy (SCIT/SLIT tablets) and the most established commercial competitor in the broader allergy space. Carsten Hellmann, former CEO of ALK-Abello, is on Aravax's board, signaling strategic overlap and a potential partnership/acquisition path.

Emerging players

• Intrommune Therapeutics: Intrommune is developing a peanut allergy immunotherapy delivered via a toothpaste-based oral mucosal platform. It is an emerging player in the peanut allergy space using a differentiated delivery mechanism but targeting the same patient population.
• Vedanta Biosciences: Vedanta is developing microbiome-based immunotherapies including for food allergy. While mechanism differs (commensal bacteria vs peptide), it targets the same underlying indication category and represents an emerging competitive approach in food allergy treatment that Aravax will need to position against.
• Prota Therapeutics: Prota Therapeutics (formerly Prota Kids) is developing peanut oral immunotherapy with a probiotic-based approach, in clinical-stage development for peanut allergy. It is a direct emerging competitor in peanut allergy immunotherapy with overlapping indication and allergy-specialist channel.
• COUR Pharmaceuticals: COUR Pharmaceuticals develops nanoparticle-based antigen-specific immune tolerance therapies for food allergies including peanut. It represents an emerging approach (antigen-loaded nanoparticles) intersecting with Aravax's peptide immunotherapy space in the same indication and prescriber audience.

Direct peers

• Aimmune Therapeutics: Aimmune developed and commercialized Palforzia, the first FDA-approved oral immunotherapy for peanut allergy. It is the most directly comparable company to Aravax in peanut allergy immunotherapy, with overlapping target indication and clinical-stage development path. Andrew Oxtoby (now on Aravax's board) was previously CCO at Aimmune.
• Alladapt Immunotherapeutics: Alladapt is developing a multi-food allergen immunotherapy for peanut plus other foods, with a similar mechanism approach (allergen-specific immune modulation). Louise Peacock, Aravax's Chief Regulatory and Quality Officer, previously held the same role at Alladapt, indicating direct competitive and talent overlap.
• DBV Technologies: DBV develops Viaskin, an epicutaneous immunotherapy patch for peanut and other food allergies. It is a direct competitor in the food allergy immunotherapy space using an alternative delivery modality (patch vs Aravax's intradermal peptide), targeting the same patient population and allergist channel.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/aravax

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Subsidiaries1 record

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aravax